Regeneron Pharmaceuticals (REGN) Operating Expenses (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Operating Expenses of $3.0 billion for Q2 2026, up 15.45% year-over-year from $2.6 billion in Q2 2025, and up 1.17% quarter-over-quarter from $3.0 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Operating Expenses (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Operating Expenses history runs 18 years deep, the most recent figure standing at $3.0 billion for Q2 2026.
- In Q2 2026, Operating Expenses rose 15.45% year-over-year to $3.0 billion; the TTM figure through Jun 2026 stood at $11.7 billion (up 12.71% YoY), while the FY2025 annual figure was $10.8 billion, up 5.42% from the prior year.
- Operating Expenses for Q2 2026 stood at $3.0 billion, up from $3.0 billion in the prior quarter.
- The five-year high for Operating Expenses was $3.0 billion in Q4 2025, with the low at $1.7 billion in Q1 2022.
- The 5-year median for Operating Expenses is $2.4 billion (2023), against an average of $2.4 billion.
- The sharpest annual moves came in 2022 and 2023: Operating Expenses retreated 2.46% in 2022, then jumped 31.49% in 2023.
- Regeneron Pharmaceuticals' Operating Expenses stood at $2.3 billion in 2022, then gained by 8.55% to $2.5 billion in 2023, then gained by 13.72% to $2.8 billion in 2024, then advanced by 7.34% to $3.0 billion in 2025, then slipped by 0.24% to $3.0 billion in 2026.
- Business Quant data shows REGN's Operating Expenses at $3.0 billion in Q2 2026, $3.0 billion in Q1 2026, and $3.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 367.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.00 Bn |
| Mar 31, 2026 | 2.96 Bn |
| Dec 31, 2025 | 3.00 Bn |
| Sep 30, 2025 | 2.73 Bn |
| Jun 30, 2025 | 2.60 Bn |
| Mar 31, 2025 | 2.44 Bn |
| Dec 31, 2024 | 2.80 Bn |
| Sep 30, 2024 | 2.54 Bn |
| Jun 30, 2024 | 2.48 Bn |
| Mar 31, 2024 | 2.39 Bn |
| Dec 31, 2023 | 2.46 Bn |
| Sep 30, 2023 | 2.25 Bn |
| Jun 30, 2023 | 2.14 Bn |
| Mar 31, 2023 | 2.22 Bn |
| Dec 31, 2022 | 2.27 Bn |
| Sep 30, 2022 | 1.71 Bn |
| Jun 30, 2022 | 1.75 Bn |
| Mar 31, 2022 | 1.71 Bn |
| Dec 31, 2021 | 2.31 Bn |
| Sep 30, 2021 | 1.61 Bn |